Intercell Ag

Valneva Austria Gmbh

Arsanis Biosciences Gmbh

X4 Pharmaceuticals (austria) Gmbh

Janssen Pharmaceuticals, Inc.

Cebina Gmbh

Intercell Austria Ag

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Eveliqure Biotechnologies Gmbh

X4 Pharmaceuticals, Inc.

Eszter Nagy

Andreas Meinke

Markus Hanner

Alexander Von Gabain

Gábor Nagy

Irina Mirkina

Adriana Badarau

Wolfgang Zauner

Valéria Szijárto

Jolanta Lukasiewicz

Ulrike Stierschneider

Gerhild Zauner

Claire M Fraser

Urban Lundberg

Agnieszka Dryla

Uwe Von Ahsen

Markus Horky

Sonja Prustomersky

Tamas Henics

Brigitte Tempelmaier

Beatrice Senn

Astrid Teubenbacher

Manuel Zerbs

Robert Konrat

Zóltan Magyarics

Bianka Prinz

Laura M Walker

Dieter Gelbmann

Luis Guachalla

Birgit Noiges

Christoph Klade

Oresta Vytvytska

Jutta Pikalo

Steven Gill

Thomas Weichhart

Martin Hafner

Hildegard Etz

Duc Bui Minh

Sabine Kallenda

Zoltán Magyarics

Christina Satke

Manfred Berger

Frank Mattner

Michael Buschle

Katherine Cohen

Jörg Fritz

Christina Neubauer

Valeria Szijárto

Luis Gauchalla

Duc Min Bui

Christine Triska

Albina Poljak

Birgit Winkler

Shailesh Dewasthaly

Dagmar Zierer

Zehra Visram

Barbara Maierhofer

Beatrice Tschanun

Thomas Cipps

Sharmila Bakshi

Wolfgang Schueler

Gäbor Nagy

Maximiliano Vasquez

Tamás Henics

Lukas Stulik

Michael Benjamin Battles

Carmen Giefing-Krōll

Ivana Dolezilkova

Michaela Jaegerhofer

Brigitre Tempelmaier

Katharina Ramoni

Tim Rollenske

Harald Rouha

Min Bui Duc

Sanja Selak

Margarita Smidt

Michaela Weissgram

Stefan Seidel

Julia Bacher

Martin Oleksiewicz

Hedda Wardemann

Michael Schunn

Carmen Giefing

Valeria Szijarto

Nels Nielson

Duc Minh Bui

Jorg Fritz

Zoltan Magyarics

Gabor Nagy

Tushar S Jain

Bianka Dominique Prinz

Jolanta Katarzyna Lukasiewicz

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR)strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

MDRimmunogen

The invention refers to an isolated antibody that specifically binds to O25b antigen ofstrains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG., and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG., or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

specific antibodies

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody. 

Antibodies targeting a galactan-based O-antigen of K. pneumoniae

A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 &#x3bc;g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Antiviral treatment

A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 &#x3bc;g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

MDRspecific antibody

A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

O3 specific antibodies

[object Object]

The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

A live attenuatedvaccine, which is based on a roughstrain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and astrain, which is a2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutatedinvasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.

Live attenuated Shigella vaccine

The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from, and methods for isolating such antigens and specific uses thereof.

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R&#x2014;XZXZXZX&#x2014;R, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and Rand Rare selected independently one from the other from the group consisting of &#x2014;H, &#x2014;NH, &#x2014;COCH, &#x2014;COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X&#x2014;Rmay also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.

Vaccine composition comprising an antigen and a peptide having adjuvant properties

The invention relates to a composition comprising at least two protective proteins against() or functionally active variant thereof; a protective peptide against; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing ainfection; a method for identifying a ligand capable of binding the composition and/or at least one protective peptide; and the use of the composition and/or at least one protective peptide for the isolation and/or purification and/or identification of an interaction partner of the composition and/or peptide.

Growing community of inventors

Vienna, Austria

Eszter Nagy